Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - ranitidine hydrochloride - oral tablet - 150mg

Bandaríkin - enska - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine is indicated in: concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; gerd; and erosive esophagitis. ranitidine is contraindicated in patients known to have hypersensitivity to the drug or any of the ingredients (see precautions ).

Bandaríkin - enska - NLM (National Library of Medicine)

avkare, inc - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine is indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out for 1 year. -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - ranitidine hydrochloride -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - ranitidine hydrochloride -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - ranitidine hydrochloride -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - ranitidine hydrochloride -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - ranitidine hydrochloride -

Bandaríkin - enska - NLM (National Library of Medicine)

unit dose services - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 15 mg in 1 ml - ranitidine oral solution usp is indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried

Kanada - enska - Health Canada

sivem pharmaceuticals ulc - ranitidine (ranitidine hydrochloride) - tablet - 150mg - ranitidine (ranitidine hydrochloride) 150mg - histamine h2-antagonists